Clinical trials: Recurrent Adenocarcinoma
Anaplastic Thyroid Cancer, Insular Thyroid Cancer
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
Phase II trial to study the effectiveness of sorafenib tosylate in treating patients who have locally advanced, metastatic, or locally recurrent thyroid cancer.
- Conditions
- Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage III Follicular Thyroid Cancer
- Trial name
- NCT00095693
- Testing
- sorafenib tosylate, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Colon Cancer, Colon Adenocarcinoma
Survival Outcomes by Tumor-Node Stage and Recurrence Patterns in Colon Cancer After Radical Surgery
Colon cancer is one of the most common cancers worldwide, and even after curative (radical) surgery, some patients develop recurrence or distant metastasis.
- Conditions
- Colon Cancer, Colon Adenocarcinoma, Colon Cancer Stage III, Colon Cancer Stage I
- Trial name
- STARS (NCT07167147)
- Where
- Taiwan
- Volunteers
- 7,259 people
- Sponsor
- Chang Gung Memorial Hospital
Kidney Cancer
Lymphocyte Therapy in Treating Patients With Kidney Cancer
RATIONALE: Treating a person's lymphocytes with interleukin-2 and monoclonal antibody may help them kill more cancer cells when they are put back in the body.
- Trial name
- NCT00002589
- Testing
- aldesleukin, muromonab-CD3, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00057889
- Testing
- ipilimumab
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Kidney Cancer
Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer
Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have metastatic kidney cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003968
- Testing
- bryostatin 1
- Where
- 17 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma, Hepatitis C Virus Infection
Treatment With IFN After Curative Resection of HCC in HCV-Related Cirrhosis
We conducted a randomized controlled trial of adjuvant interferon (IFN) therapy in patients with hepatitis-C virus (HCV)-related cirrhosis who underwent curative resection of hepatocellular carcinoma (HCC) to investigate whether…
- Conditions
- Hepatocellular Carcinoma, Hepatitis C Virus Infection, Liver Cirrhosis, Interferon Treatment
- Trial name
- NCT00273247
- Testing
- Interferon alpha-2b
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute, Milan
Resectable Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Ductal Adenocarcinoma
Recurrent Disease Detection After Resection of Pancreatic Adenocarcinoma Using a Standardized Surveillance Strategy
A randomized controlled trial, nested within an existing prospective cohort (Dutch Pancreatic Cancer Project; PACAP) and the United Kingdom (UK) Pancreas Cancer: Observations of Practice and survival; PACOPS) according to the…
- Trial name
- RADAR-PANC (NCT04875325)
- Testing
- Standardized surveillance
- Where
- 11 sites in Netherlands, United Kingdom
- Volunteers
- 306 people
- Sponsor
- UMC Utrecht
Kidney Cancer
Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer
RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of kidney cancer. PURPOSE: This phase II trial is studying how well interferon alfa works in treating patients with metastatic kidney…
- Trial name
- NCT00278174
- Testing
- recombinant interferon alpha-1b
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Case Comprehensive Cancer Center
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
This phase I trial studies the side effects and best dose of CPI-613 when given together with combination chemotherapy in treating patients with metastatic pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01835041
- Testing
- 6,8-bis(benzylthio)octanoic acid, oxaliplatin, leucovorin calcium
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Adenocarcinoma, Advanced Malignant Solid Neoplasm
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
This phase 1/2 trial tests the safety and effectiveness of a cancer vaccine called Labvax 3(22)-23 and GM-CSF alone or in combination with pembrolizumab in treating adenocarcinoma that has spread to other places in the body…
- Conditions
- Advanced Adenocarcinoma, Advanced Malignant Solid Neoplasm, Metastatic Adenocarcinoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT05101356
- Testing
- Antineoplastic Vaccine, Sargramostim, Pembrolizumab
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of California, Davis
Hepatocellular Carcinoma (HCC)
Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
A Study of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients with Unresectable Recurrent/Metastatic Hepatocellular Carcinoma.
- Trial name
- NCT07487402
- Testing
- Metabolically Armed GPC3 CAR-T cells
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Zhejiang University
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
The purpose of this study is to study the effects of EPI-7386 in combination with Enzalutamide on participants diagnosed with prostate cancer.
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- NCT06312670
- Testing
- EPI-7386, Enzalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pedro Barata, MD, MSc
Stage IV Prostate Cancer, Bone Metastases
Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Ketoconazole may suppress the production of hormones and may interfere in the growth of prostate cancer cells. Alendronate sodium may be effective in preventing bone metastases and bone pain associated with prostate…
- Conditions
- Stage IV Prostate Cancer, Bone Metastases, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
- Trial name
- NCT00019695
- Testing
- alendronate sodium, ketoconazole
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00055822
- Testing
- oblimersen sodium, fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prostate Cancer (Adenocarcinoma), Prostate Specific Antigen
Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
The purpose of this study is to assess detection rate of flotufolastat F 18 positron emission tomography (PET) for low prostate specific antigen (PSA) recurrence of prostate cancer (PC) following radical prostatectomy.
- Trial name
- NCT06862856
- Testing
- Positron Emission Tomography (PET)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Prostate Cancer
Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00077402
- Testing
- fenretinide
- Where
- 6 sites in Australia, Hong Kong and 1 more
- Volunteers
- 50 people
- Sponsor
- Cancer Therapeutics Research Group
Prostate Cancer
Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Vaccines made from a patient's white blood cells may make the body build an immune response to kill cancer cells. Interleukin-12 may kill cancer cells by stopping blood flow to the tumor and by stimulating a person's…
- Trial name
- NCT00015977
- Testing
- PSA prostate cancer vaccine, recombinant interleukin-12
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Chicago
Pancreatic Adenocarcinoma, Pancreatic Cysts
Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors
This multicenter randomized trial aims to primarily assess and compare the functional recovery of patients who undergo open versus robotic pancreaticoduodenectomy for benign and malignant lesions of the head of the pancreas.
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Cysts, Pancreatic Endocrine Tumors, Chronic Pancreatitis
- Trial name
- PORTAL (NCT04400357)
- Testing
- Robotic pancreaticoduodenectomy, Open pancreaticoduodenectomy
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Ruijin Hospital
Lung Cancer
Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Lometrexol may stop or slow the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Folic acid may be effective in preventing or lessening the side effects of lometrexol.
- Trial name
- NCT00033722
- Testing
- folic acid, lometrexol
- Where
- 7 sites in United States
- Sponsor
- Tularik
Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer
Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well tivantinib with or without erlotinib hydrochloride works in treating patients with metastatic or locally advanced kidney cancer that cannot be removed by surgery.
- Conditions
- Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma
- Trial name
- NCT01688973
- Testing
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Tivantinib
- Where
- 214 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)